

**DATES:** Comments should be received on or before November 29, 2010 to be assured of consideration.

**ADDRESSES:** Comments may be submitted electronically on <http://www.regulations.gov> or by mail to Office of Information and Regulatory Affairs, 725 17th Street, NW., Washington, DC 20038 Attn: OMB 3048-0016.

**SUPPLEMENTARY INFORMATION:**

*Titles and Form Number:* EIB 92-36 Application for Issuing Bank Credit Limit under Letter of Credit Insurance Policy.

*OMB Number:* 3048-0016.

*Type of Review:* Regular.

*Need and Use:* The Application for Issuing Bank Credit Limit under Letter of Credit Insurance Policy will be used to determine the eligibility of the issuing bank and the transaction for Export Import Bank assistance under its insurance program.

**Sharon A. Whitt,**

*Agency Clearance Officer.*

[FR Doc. 2010-27253 Filed 10-27-10; 8:45 am]

**BILLING CODE 6690-01-P**

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 22, 2010.

A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President), 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *Vogel Bancshares, Inc.*, Orange City, Iowa; to acquire up to 100 percent of the voting shares of Farmers Savings Bank, Remsen, Iowa.

B. Federal Reserve Bank of San Francisco (Kenneth Binning, Vice President, Applications and Enforcement), 101 Market Street, San Francisco, California 94105-1579:

1. *Carpenter Fund Manager GP, LLC, Carpenter Fund Management Company, LLC, Carpenter Community Bancfund, L.P., Carpenter Community Bancfund—A, L.P., Carpenter Community Bancfund—CA, L.P., CGB Holdings, Inc., CCFW, Inc., and SCJ, Inc.*; all of Irvine, California; to acquire 100 percent of the voting shares of Professional Business Bank, Pasadena, California, which will merge with California General Bank, Pasadena, California.

In connection with this Application, CGB Holdings, Inc., Irvine, California, has applied to acquire 100 percent of the voting shares of CGB Asset Management, Inc., Irvine, California, and thereby engage in extending credit and servicing loans, pursuant to section 225.28(b)(1) of Regulation Y.

Board of Governors of the Federal Reserve System, October 25, 2010.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 2010-27280 Filed 10-27-10; 8:45 am]

**BILLING CODE 6210-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Public Meeting of the Presidential Commission for the Study of Bioethical Issues

**AGENCY:** Department of Health and Human Services, Office of the Assistant Secretary for Health, The Presidential Commission for the Study of Bioethical Issues.

**ACTION:** Notice of Meeting.

**SUMMARY:** The Presidential Commission for the Study of Bioethical Issues (PCSBI) will conduct its third meeting in November. At this meeting, the Commission will continue discussing the emerging science of synthetic biology, including its potential benefits and risks, and appropriate ethical

boundaries and principles. The Commission will develop and finalize recommendations concerning any actions that the Federal Government should take to ensure that America reaps the benefits of this developing field of science while identifying appropriate ethical boundaries and minimizing risks. It will also identify suggestions for future study, if any.

**DATES:** The meeting will take place Tuesday, November 16, 2010, from 10:30 a.m. to approximately 4:15 p.m., and Wednesday, November 17, 2010, from 9 a.m. to approximately 11:30 a.m.

**ADDRESSES:** Emory Conference Center Hotel, 1615 Clifton Road, Atlanta, GA 30329. Phone 404-712-6000.

**FOR FURTHER INFORMATION CONTACT:** Judy Crawford, The Presidential Commission for the Study of Bioethical Issues, 1425 New York Avenue, NW., Suite C-100, Washington, DC 20005. Telephone: 202/233-3960. E-mail: [judy.crawford@bioethics.gov](mailto:judy.crawford@bioethics.gov). Additional information may be obtained by viewing the Web site: <http://www.bioethics.gov>.

**SUPPLEMENTARY INFORMATION:** Pursuant to the Federal Advisory Committee Act, Public Law 92-463, as amended 5 U.S.C. App., notice is hereby given of the third meeting of the PCSBI. The meeting will be held from 10:30 a.m. to approximately 4:15 p.m. on Tuesday, November 16, 2010, and from 9 a.m. to approximately 11:30 a.m. on Wednesday, November 17, 2010, at the Emory Conference Center Hotel, Atlanta, GA. The meeting will be open to the public with attendance limited to space available. The meeting will also be Web cast at <http://www.bioethics.gov>.

Under authority of Executive Order 13521, dated November 24, 2009, the President established the PCSBI to serve as a public forum and advise him on bioethical issues generated by novel and emerging research in biomedicine and related areas of science and technology. The Commission is charged to identify and promote policies and practices that assure ethically responsible conduct of scientific research, healthcare delivery, and technological innovation. In undertaking these duties, the Commission will examine specific bioethical, legal, and social issues related to potential scientific and technological advances; examine diverse perspectives and explore possibilities for useful international collaboration on these issues, and recommend legal, regulatory, or policy actions as appropriate. The main agenda items for this third meeting involve further discussion of the opportunities and benefits to the public of the